For the twelve months ended Jun 30, 2026, AIM ImmunoTech Inc. reported $95.0K of revenue and -$14.27M of net income.
AIM revenue was $26.0K in fiscal Q2 2026 (ended Jun 30, 2026), up 4.0% from a year earlier and up 18.2% from the prior quarter. For the full fiscal 2025 it was $88.0K, down 48.2% from fiscal 2024. Compound annual growth was -11.6% over 5 years and -4.0% over 10 years. It rose in 4 of the last 10 fiscal years.
AIM net income was -$3.79M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$2.79M a year earlier. For the full fiscal 2025 it was -$13.96M, compared with -$17.32M in fiscal 2024.
AIM diluted EPS was -$0.43 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$8.62.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88.0K | $170.0K | $202.0K | $141.0K | $135.0K | $163.0K | $140.0K | $367.0K | $437.0K | $92.0K |
| Research and development | $3.92M | $6.20M | $10.94M | $6.99M | $7.67M | $5.72M | $4.65M | $4.78M | $4.10M | $5.11M |
| Selling, general and admin | $7.70M | $13.71M | $21.14M | $13.07M | $8.67M | $8.65M | $7.04M | $6.20M | $6.57M | $7.68M |
| Operating income | -$11.66M | -$19.77M | -$31.92M | -$19.92M | -$18.84M | -$15.15M | -$12.44M | -$11.50M | -$11.42M | -$13.80M |
| Interest expense | $812.0K | $585.0K | - | - | $67.0K | $672.0K | $427.0K | $201.0K | - | - |
| Pre-tax income | -$13.96M | - | - | - | - | - | - | - | - | - |
| Net income | -$13.96M | -$17.32M | -$28.96M | -$19.45M | -$19.13M | -$14.40M | -$9.40M | -$9.83M | -$8.26M | -$7.50M |
| EPS, basic | -$8.62 | -$30.92 | -$60.00 | -$40.00 | -$40.00 | -$45.00 | -$258.00 | -$977.00 | -$1276.00 | -$1496.00 |
| EPS, diluted | -$8.62 | -$30.92 | -$60.00 | -$40.00 | -$40.00 | -$45.00 | -$258.00 | -$977.00 | -$1276.00 | -$1496.00 |
| Diluted shares | 1.6M | 560,169 | 485,854.04 | 480,472.88 | 473,399.75 | 318,427.99 | 36,427.17 | 10,043 | 6,517.29 | 4,958.683 |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.98M | $1.70M | $5.44M | $27.05M | $32.09M | $38.50M | $1.47M | $299.0K | $1.41M | $2.41M |
| Short-term investments | $62.0K | $2.28M | $7.63M | $7.14M | $16.18M | $15.88M | $7.31M | - | - | - |
| Receivables | $7.0K | - | $1.18M | $1.68M | - | $34.0K | $44.0K | $235.0K | $24.0K | - |
| Current assets | $3.29M | $4.18M | $14.56M | $36.32M | $50.21M | $40.31M | $10.45M | $3.80M | $3.50M | $6.94M |
| Total assets | $5.78M | $8.61M | $19.38M | $40.49M | $57.70M | $64.58M | $20.75M | $13.85M | $14.21M | $18.87M |
| Current liabilities | $6.22M | $9.54M | $8.65M | $1.36M | $673.0K | $1.10M | $1.13M | $5.29M | $2.71M | $2.44M |
| Short-term debt | $3.55M | $2.31M | - | - | - | $230.0K | $214.0K | $199.0K | - | - |
| Long-term debt | $927.0K | - | - | - | - | $1.88M | $2.10M | $2.32M | - | - |
| Total debt | $4.48M | $2.81M | - | - | - | $2.11M | $2.32M | $2.52M | $1.83M | - |
| Total liabilities | $15.56M | $9.93M | $9.15M | $2.02M | - | - | - | - | - | - |
| Shareholders' equity | -$9.78M | -$1.32M | $10.23M | $38.47M | $56.88M | $61.29M | $13.44M | $5.58M | $8.70M | $15.50M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.96M | -$14.89M | -$21.27M | -$16.11M | -$13.96M | -$10.37M | -$9.07M | -$10.64M | -$7.94M | -$7.38M |
| Capital expenditures | - | $18.0K | - | $86.0K | $41.0K | $22.0K | $68.0K | $51.0K | $20.0K | $160.0K |
| Free cash flow | - | -$14.91M | - | -$16.19M | -$14.01M | -$10.39M | -$9.13M | -$10.69M | -$7.96M | -$7.54M |
| Investing cash flow | $1.85M | $4.71M | -$832.0K | $10.99M | -$631.0K | -$9.16M | -$6.15M | $92.0K | $2.73M | $2.92M |
| Financing cash flow | $10.39M | $6.44M | $485.0K | $80.0K | $8.19M | $56.56M | $16.39M | $9.44M | $4.21M | $4.76M |
| Stock-based compensation | $60.0K | $686.0K | $243.0K | $954.0K | $1.57M | $1.04M | $853.0K | $929.0K | $571.0K | $52.0K |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -48.2% | -15.8% | 43.3% | 4.4% | -17.2% | 16.4% | -61.9% | -16.0% | 375.0% | -30.8% |
| Operating margin | -13254.5% | -11630.6% | -15800.0% | -14129.8% | -13954.1% | -9295.7% | -8887.9% | -3132.4% | -2612.4% | -15004.3% |
| Net margin | -15861.4% | -10188.2% | -14337.6% | -13790.8% | -14168.1% | -8834.4% | -6717.1% | -2677.7% | -1889.9% | -8154.3% |
| Free cash flow margin | - | -8768.2% | - | -11485.1% | -10374.8% | -6374.2% | -6525.0% | -2913.1% | -1821.7% | -8195.7% |
| Return on equity | - | - | -283.0% | -50.5% | -33.6% | -23.5% | -70.0% | -176.1% | -94.9% | -48.4% |
| Return on assets | -241.4% | -201.2% | -149.4% | -48.0% | -33.1% | -22.3% | -45.3% | -71.0% | -58.1% | -39.7% |
| Current ratio | 0.53 | 0.44 | 1.68 | 26.69 | 74.61 | 36.58 | 9.27 | 0.72 | 1.29 | 2.85 |
| Debt to equity | - | - | - | - | - | 0.03 | 0.17 | 0.45 | 0.21 | - |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $26.0K | $22.0K | $21.0K | $26.0K | $25.0K | $16.0K | $45.0K | $35.0K | $50.0K | $40.0K | $65.0K | $46.0K |
| Research and development | $589.0K | $482.0K | $1.06M | $607.0K | $1.17M | $1.08M | $1.66M | $1.44M | $1.15M | $1.95M | $3.20M | $2.73M |
| Selling, general and admin | $2.94M | $1.76M | $1.87M | $1.80M | $1.49M | $2.54M | $4.23M | $3.08M | $2.59M | $3.81M | $10.86M | $5.44M |
| Operating income | -$3.51M | -$2.23M | -$2.95M | -$2.45M | -$2.65M | -$3.62M | -$5.86M | -$4.49M | -$3.69M | -$5.73M | -$14.00M | -$8.16M |
| Interest expense | $295.0K | $304.0K | $391.0K | $148.0K | $149.0K | $124.0K | $132.0K | $202.0K | $179.0K | $72.0K | - | - |
| Net income | -$3.79M | -$3.02M | -$4.17M | -$3.28M | -$2.79M | -$3.71M | -$5.97M | -$3.70M | -$1.84M | -$5.82M | -$12.58M | -$7.82M |
| EPS, basic | -$0.43 | -$0.69 | - | $1.57 | -$3.68 | -$0.05 | -$9.92 | -$6.00 | -$3.00 | -$12.00 | -$26.00 | -$16.00 |
| EPS, diluted | -$0.43 | -$0.69 | - | $1.57 | -$3.68 | -$0.05 | -$9.92 | -$6.00 | -$3.00 | -$12.00 | -$26.00 | -$16.00 |
| Diluted shares | 17.1M | 4.4M | - | 2.1M | 759,289 | 703,298 | - | 576,770 | 528,374 | 494,580.23 | - | 486,351.65 |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $9.90M | $5.82M | $2.98M | $2.35M | $476.0K | $898.0K | $1.70M | $915.0K | $3.55M | $3.29M | $5.44M | $15.26M |
| Short-term investments | $64.0K | $63.0K | $62.0K | $62.0K | $359.0K | $1.35M | $2.28M | $6.29M | $6.51M | $7.65M | $7.63M | $7.17M |
| Receivables | - | - | $7.0K | - | - | - | - | - | - | - | $1.18M | $48.0K |
| Current assets | $10.43M | $6.21M | $3.29M | $2.58M | $1.02M | $2.58M | $4.18M | $7.57M | $10.36M | $11.31M | $14.56M | $22.74M |
| Total assets | $12.73M | $8.59M | $5.78M | $5.49M | $4.13M | $6.25M | $8.61M | $13.59M | $15.71M | $16.19M | $19.38M | $27.86M |
| Current liabilities | $4.95M | $6.14M | $6.22M | $4.04M | $10.39M | $9.77M | $9.54M | $10.10M | $8.84M | $9.88M | $8.65M | $4.72M |
| Short-term debt | $3.62M | $4.00M | $3.55M | $1.88M | $2.29M | $1.95M | $2.31M | $2.59M | $2.35M | $1.62M | - | - |
| Long-term debt | - | $210.0K | $927.0K | - | - | - | - | $139.0K | $283.0K | $950.0K | - | - |
| Total debt | $3.62M | $4.21M | $4.48M | - | $2.72M | $2.39M | $2.81M | $2.73M | $2.64M | $2.57M | - | - |
| Total liabilities | $4.99M | $6.46M | $15.56M | $11.57M | $10.68M | $10.11M | $9.93M | $10.68M | $9.61M | $11.36M | $9.15M | - |
| Shareholders' equity | $7.74M | $2.13M | -$9.78M | -$6.08M | -$6.55M | -$3.86M | -$1.32M | $2.91M | $6.10M | $4.83M | $10.23M | $22.60M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.59M | -$2.72M | -$1.99M | -$5.08M | -$1.53M | -$2.36M | -$3.96M | -$3.11M | -$3.01M | -$4.82M | -$9.76M | -$5.67M |
| Capital expenditures | - | - | - | - | - | - | $0 | - | - | - | - | - |
| Free cash flow | - | - | - | - | - | - | -$3.96M | - | - | - | - | - |
| Investing cash flow | -$112.0K | -$37.0K | -$95.0K | $296.0K | $754.0K | $898.0K | $3.70M | $334.0K | $826.0K | -$158.0K | -$214.0K | -$336.0K |
| Financing cash flow | $8.79M | $5.59M | $2.72M | $6.65M | $355.0K | $660.0K | $1.04M | $137.0K | $2.44M | $2.83M | $147.0K | $233.0K |
| Stock-based compensation | - | - | $0 | $0 | $0 | $60.0K | $196.0K | $80.0K | $80.0K | $80.0K | $61.0K | $50.0K |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 4.0% | 37.5% | -53.3% | -25.7% | -50.0% | -60.0% | -30.8% | -23.9% | 19.0% | -18.4% | 16.1% | 119.0% |
| Operating margin | -13511.5% | -10118.2% | -14057.1% | -9411.5% | -10584.0% | -22618.8% | -13011.1% | -12825.7% | -7388.0% | -14335.0% | -21544.6% | -17732.6% |
| Net margin | -14569.2% | -13740.9% | -19881.0% | -12630.8% | -11176.0% | -23156.3% | -13260.0% | -10571.4% | -3672.0% | -14542.5% | -19347.7% | -16991.3% |
| Free cash flow margin | - | - | - | - | - | - | -8788.9% | - | - | - | - | - |
| Current ratio | 2.11 | 1.01 | 0.53 | 0.64 | 0.10 | 0.26 | 0.44 | 0.75 | 1.17 | 1.14 | 1.68 | 4.82 |
| Debt to equity | 0.47 | 1.98 | - | - | - | - | - | 0.94 | 0.43 | 0.53 | - | - |
Source: XBRL data AIM ImmunoTech Inc. files with the SEC, latest filing dated Aug 7, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-44, first reported Aug 14, 2019; 1-for-100, first reported Aug 14, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| AIM | $95.0K | -21.5% | -$14.27M | -15021.1% | $6.5M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |